secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2026-10-15T21:08:27+00:00
Accession:  0001493152-26-047278
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ChronoScale Q1 revenue $41.5M, up 148% YoY; net loss widens to $26.4M
---------------------------------------------------------------------

- Revenue $41.5M vs $16.7M a year ago (+148%), driven by AI infrastructure hardware resale to a new customer; cost of revenues $45.6M, up 91% YoY.
- Net loss from continuing operations $26.4M ($0.18 basic/diluted) vs $11.2M ($0.08) prior year; Adjusted EBITDA $5.9M vs $9.4M.
- Secured 50 MW AI compute deployment with Microsoft in North America using NVIDIA GB300 NVL72 systems; also Nutanix partnership and 3-year Baseten Labs deal (~4 MW, completion calendar Q1 2027).
- Sold Legacy Ekso Business on Sept 30, 2026; discontinued-operations net loss $16.1M; cash and equivalents $15.2M as of Aug 31, 2026.
- Received $328.2M in aggregate customer prepayments; contract extension plus new customer agreement puts company on track for $1B annualized run-rate revenue by calendar Q3 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000149315226047278/0001493152-26-047278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000149315226047278/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-047278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer